Loading…
avatar for Prof. Markus Peck-Radosavljevic

Prof. Markus Peck-Radosavljevic

Associate Professor of Medicine at the Medical University Vienna

Professor Markus Peck-Radosavljevic, MD is Associate Professor of Medicine and Vice-Chairman at the Department of Gastroenterology and Hepatology at the Medical University of Vienna, Austria. He is a fellow of the Austrian College of Physicians (Internal Medicine, Gastroenterology / Hepatology, Infectious Diseases, and Intensive Care Medicine) and a member of several professional organisations including the American Association for the Study of Liver Disease, the European Association for the Study of the Liver (EASL), the American Gastroenterologic Association, the Austrian Transplant Association, the Austrian Society for Infectious Diseases and the Austrian Association for Gastroenterology and Hepatology.
Professor Peck is currently the Secretary General of the Austrian Association for Internal Medicine; he serves as Vice-secretary of EASL and is to become Secretary General of EASL in 2013.


Professor Peck began his research in liver disease by investigating into the complications of portal hypertension and cirrhosis including haematologic abnormalities. He has published several reports on thrombocytopenia and thrombopoietin in liver disease and liver transplantation as well as the haematologic side effects of antiviral therapy in chronic hepatitis C. Professor Peck has been co-investigator in trials of pegInterferon (pegIFN) in liver transplant patients and principal investigator in trials of pegIFN in haemodialysis patients with chronic hepatitis C, treatment of chronic hepatitis B, and combination antiviral therapy in HIV/HCV coinfected patients.


Over the last few years, Professor Peck has been leading the portal hypertension and hepatocellular carcinoma (HCC) Study Group at the Medical University of Vienna, Austria. He is currently researching into advanced stage liver disease with a special focus on HCC. Professor Peck is currently conducting a number a clinical trials investigating locoregional as well as systemic treatments in the first and second line setting for HCC, for all of which he is  principal investigator in Austria. In addition, he is running a translational lab testing novel approaches to the treatment of HCC.